Political framework

The Global Partnership on Drug Policies and Development (GPDPD) is the first development cooperation project to combine the alternative development and health care approaches and the associated objectives and methods anchored in the German Federal Government's drug policy.

GPDPD is integrated into the international drugs legislation framework, which is defined by the three United Nations Conventions on Drugs of 1961, 1971 and 1988. In line with the measures required by the Political Declaration and the United Nations Plan of Action on the World Drug Problem (2009), Germany is also called upon to contribute to a substantial reduction in the cultivation, trade and consumption of licit and illicit drugs worldwide. The German Federal Government's international commitment on drug policy is guided by the principle of shared responsibility between producer and consumer countries and by the principle of a balanced approach to supply and demand reduction. Both principles are set out in the United Nations Political Declaration on the World Drug Problem (2009).

The European policy framework for GPDPD’s work is set down in the EU Drugs Strategy and the EU Action Plan on Drugs, both of 2013. At national level, the Federal Government's Drug Commissioner, Marlene Mortler, implements the National Strategy on Drug and Addiction Policy (2012).

The Federal Ministry for Economic Cooperation and Development (BMZ)’s new strategy "Rethinking the Approach of Alternative Development (2013)" provides the guidelines for the Federal Government's development policy commitment in countries heavily affected by the cultivation of drugs.

There is currently strong demand on the international level for drug policy approaches that promote harm reduction. They focus on reducing the negative impact of drug use on consumers and society as a whole. In the case of substitution therapy, for example, the German Federal Government sets international standards. It also specifically targets the prevention of HIV infections, of which around one tenth in global terms is attributable to intravenous drug use.

This website is using cookies. By using our website you agree to the use of cookies. Read more on data protection.Close